120 related articles for article (PubMed ID: 11853162)
1. Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor.
Takeuchi M; Tatsumi Y; Kitaichi K; Baba K; Suzuki R; Shibata E; Takagi K; Miyamoto K; Hasegawa T; Takagi K
Biol Pharm Bull; 2002 Feb; 25(2):184-7. PubMed ID: 11853162
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis.
Wang W; Masu K; Tamura G; Suzuki K; Ohwada K; Okuyama K; Shirato K; Takayanagi M; Ohno I
Biol Pharm Bull; 2005 Mar; 28(3):515-9. PubMed ID: 15744080
[TBL] [Abstract][Full Text] [Related]
3. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression.
Momose T; Okubo Y; Horie S; Suzuki J; Isobe M; Sekiguchi M
Int Arch Allergy Immunol; 1998 Oct; 117(2):138-45. PubMed ID: 9784658
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Santing RE; Olymulder CG; Van der Molen K; Meurs H; Zaagsma J
Eur J Pharmacol; 1995 Feb; 275(1):75-82. PubMed ID: 7774665
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Hatzelmann A; Tenor H; Schudt C
Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
[TBL] [Abstract][Full Text] [Related]
6. KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4.
Sasaki K; Manabe H
Inflamm Res; 2004 Jan; 53(1):31-7. PubMed ID: 15021978
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF.
Hallsworth MP; Giembycz MA; Barnes PJ; Lee TH
Br J Pharmacol; 1996 Jan; 117(1):79-86. PubMed ID: 8825346
[TBL] [Abstract][Full Text] [Related]
8. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition.
Yasui K; Hu B; Nakazawa T; Agematsu K; Komiyama A
J Clin Invest; 1997 Oct; 100(7):1677-84. PubMed ID: 9312165
[TBL] [Abstract][Full Text] [Related]
9. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.
Tenor H; Hatzelmann A; Church MK; Schudt C; Shute JK
Br J Pharmacol; 1996 Aug; 118(7):1727-35. PubMed ID: 8842438
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2.
Yamagami H; Nishioka T; Ochiai E; Fukushima K; Nomura M; Kasugai S; Moritani S; Yokogawa K; Miyamoto K
Biochem Pharmacol; 2003 Sep; 66(5):801-7. PubMed ID: 12948861
[TBL] [Abstract][Full Text] [Related]
11. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Ezeamuzie CI
Eur J Pharmacol; 2001 Apr; 417(1-2):11-8. PubMed ID: 11301054
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Torphy TJ; Barnette MS; Hay DW; Underwood DC
Environ Health Perspect; 1994 Dec; 102 Suppl 10(Suppl 10):79-84. PubMed ID: 7705312
[TBL] [Abstract][Full Text] [Related]
13. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
[TBL] [Abstract][Full Text] [Related]
16. Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy.
Lazzeri N; Belvisi MG; Patel HJ; Yacoub MH; Chung KF; Mitchell JA
Am J Respir Cell Mol Biol; 2001 Jan; 24(1):44-48. PubMed ID: 11152649
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
Giembycz MA
Drugs; 2000 Feb; 59(2):193-212. PubMed ID: 10730545
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin.
Teixeira MM; Miotla JM; Cooper N; Gristwood RW; Hellewell PG
Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():193-6. PubMed ID: 9698932
[TBL] [Abstract][Full Text] [Related]
19. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Ikemura T; Schwarze J; Makela M; Kanehiro A; Joetham A; Ohmori K; Gelfand EW
J Pharmacol Exp Ther; 2000 Aug; 294(2):701-6. PubMed ID: 10900250
[TBL] [Abstract][Full Text] [Related]
20. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
Silva PM; Alves AC; Serra MF; Pires AL; Silva JP; Barreto EO; Cordeiro RS; Jose PJ; Teixeira MM; Lagente V; Martins MA
Br J Pharmacol; 2001 Sep; 134(2):283-94. PubMed ID: 11564646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
